FAST FACTS
FOUNDER(S):
Daniel M. Skovronsky, MD, PhD
INNOVATION(S):
Biotechnology/Pharmaceuticals
Medical Imaging Technologies
EMPLOYEES:
16
HEADQUARTERS:
Philadelphia, PA
FOUNDED:
2005
TSC MEMBER INSTITUTION(S):
University of Pennsylvania
FUNDING AGENCY(S):
National Institutes of Health
STATUS:
Private
|
AVID RADIOPHARMACEUTICALS, INC.
ABOUT THE COMPANY:
Avid is a clinical-stage, product-focused molecular imaging company with significant expertise and IP in the field of molecular brain imaging. Chronic diseases such as Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and diabetes with mellitus affect tens of millions of people worldwide. Avid is working to develop novel molecular imaging agents that allow the detection of the earliest stages of these diseases, before clinical symptoms develop.
Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in clinical trials for the detection of Alzheimer’s disease. Avid has demonstrated proof of mechanism in human trials with these agents. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB), Parkinson’s disease (PD), and has a research project in diabetes mellitus (DM). These agents have the potential to revolutionize early diagnosis and monitoring of disease.
UNIVERSITY-BASED RESEARCH CONNECTION:
The molecular imaging agents at the core of Avid’s work were originally developed by Dr. Hank Kung at the University of Pennsylvania. Dr. Kung, Professor of Radiology and Pharmacology at the University of Pennsylvania, serves as Avid’s Chief Scientific Advisor, Chairman of the Scientific Advisory Board. He is regarded as a world leader in research and development of innovative radiopharmaceuticals for diagnosis of brain diseases including Alzheimer’s disease and Parkinson’s disease.
Avid founder Dr. Daniel Skovronsky was previously Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. He has more than 20 peer-reviewed publications and several National Institutes of Health funded grants on Alzheimer’s disease research.
ROLE OF FEDERAL RESEARCH FUNDING:
The basic research at the University of Pennsylvania that led to the development of this technology was supported by research grants from the National Institutes of Health.
 Read The Full Report Here
|
Printer-Friendly Version
AVID RADIOPHARMACEUTICALS, INC.